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Combining transcranial magnetic stimulation (TMS) and electroencephalography (EEG) constitutes a powerful tool to directly assess
human cortical excitability and connectivity. TMS of the primary motor cortex elicits a sequence of TMS-evoked EEG potentials (TEPs).
It is thought that inhibitory neurotransmission through GABA-A receptors (GABAAR) modulates early TEPs (50 ms after TMS),
whereas GABA-B receptors (GABABR) play a role for later TEPs (at100 ms after TMS). However, the physiological underpinnings of
TEPs have not been clearly elucidated yet. Here, we studied the role of GABAA/B-ergic neurotransmission for TEPs in healthy subjects
using a pharmaco-TMS-EEG approach. In Experiment 1, we tested the effects of a single oral dose of alprazolam (a classical benzodiaz-
epine acting as allosteric-positive modulator at 1, 2, 3, and 5 subunit-containing GABAARs) and zolpidem (a positive modulator
mainly at the1GABAAR) in a double-blind, placebo-controlled, crossover study. In Experiment 2, we tested the influence of baclofen (a
GABABRagonist) anddiazepam(a classical benzodiazepine) versusplaceboonTEPs.Alprazolamanddiazepam increased the amplitude
of the negative potential at 45 ms after stimulation (N45) and decreased the negative component at 100 ms (N100), whereas zolpidem
increased the N45 only. In contrast, baclofen specifically increased the N100 amplitude. These results provide strong evidence that the
N45 represents activity of 1-subunit-containing GABAARs, whereas the N100 represents activity of GABABRs. Findings open a novel
window of opportunity to study alteration of GABAA-/GABAB-related inhibition in disorders, such as epilepsy or schizophrenia.
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Introduction
Transcranial magnetic stimulation (TMS) is a noninvasive brain
stimulationmethod that allows to study human cortical function
in vivo (Hallett, 2007). However, the potential of TMS as a stand-
alone technique is limited. This potential can be enhanced by
combining TMS with simultaneous registration of electroen-
cephalography (EEG), thus providing direct information about
cortical excitability and connectivity with reasonable spatial and
excellent time resolution (Rogasch and Fitzgerald, 2013). A single
TMS pulse delivered over the primary motor cortex (M1) results
in a sequence of positive and negative EEG deflections. These
TMS-evoked cortical potentials (TEPs) last for up to 300 ms in
both the vicinity of the stimulation as well as in remote inter-
connected brain areas (Ilmoniemi et al., 1997; Bonato et al.,
2006; Lioumis et al., 2009). TMS-EEG recordings have pro-
vided important insights into cortical processing both in
health (Massimini et al., 2005; Ferrarelli et al., 2010) and dis-
ease (Rosanova et al., 2012; Ragazzoni et al., 2013). However,
the neurophysiological underpinnings of TEPs have not been
clearly elucidated yet.
Animal studies show that electrical stimulation of a cortical
area provokes an initial, brief excitation followedby twophases of
inhibition (Connors et al., 1988). The first inhibition (fast IPSP
[fIPSP]) occurs at short latencies50 ms and is linked to activa-
tion of GABA-A receptors (GABAARs). The second inhibition
(slow IPSP [sIPSP]) has a delayed onset, is long-lasting (50–200
ms), and is generated by an increase in potassium conductance
via activation of metabotropic GABA-B receptors (GABABRs)
(Connors et al., 1988;Deisz, 1999). Based on these findings, it was
hypothesized that activation of GABAARs contributes to the TEP
at 45 ms after TMS over M1 (N45), whereas activation of
GABABRs is involved in the negative deflection at100 ms after
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TMS (N100) (Nikulin et al., 2003; Ferreri et al., 2011; Bruckmann
et al., 2012; Rogasch and Fitzgerald, 2013; Farzan et al., 2013).
Here, we tested these hypotheses in healthy human subjects
by conducting two separate double-blind, placebo-controlled
pharmaco-TMS-EEG studies. In Experiment 1, we investigated the
acute effects of alprazolam, a classical benzodiazepine and
allosteric-positive modulator of 1, 2, 3, and 5 subunits of
theGABAARs, and zolpidem, whichmainly binds at1-subunit-
containing GABAARs, on TEP amplitudes. We aimed to study
the role of different -subunit-containing GABAARs as they un-
derlie different physiological functions (Mo¨hler et al., 2002), and
differentially underlie the pathophysiology of epilepsy (Cossette
et al., 2002), schizophrenia (Uhlhaas and Singer, 2012), or devel-
opmental cortical plasticity (Fagiolini et al., 2004). In Experiment
2, we studied the acute effects of baclofen, a specific GABABR
agonist, and diazepam, a classical benzodiazepine, on TEP am-
plitudes. Alprazolam and diazepam increased the N45 and de-
creased the N100 amplitude, whereas zolpidem increased the
N45 amplitude only. In contrast, baclofen specifically increased
the N100 amplitude without affecting earlier TEPs. These data
suggest that theN45 represents activity of1-subunit-containing
GABAARs, whereas the N100 represents activity of GABABRs.
These TMS-EEG findings can help to further characterize func-
tion of the GABAergic inhibitory system in health and disease.
Materials andMethods
Subjects
Twenty-two male subjects 21–32 years of age (mean age, 25.0  2.5
years) and 19 male subjects 22–32 years of age (26.4 3.5 years) partic-
ipated after giving written informed consent in Experiments 1 and 2,
respectively. Female participants were excluded in both studies because
of menstrual cycle-related effects on cortical excitability, which can be a
potential confound in TMS studies (Smith et al., 1999). All subjects were
right-handed according to the Edinburgh Handedness Inventory (later-
ality score75%) (Oldfield, 1971). Subjects underwent a physical exam-
ination before each experiment and were screened for contraindications
to TMS (Rossi et al., 2009). Exclusion criteria included the presence of a
history of neurological or psychiatric disease, use of CNS active drugs,
abuse of any drugs (including nicotine and alcohol), or contraindica-
tions to the study medications (alprazolam, zolpidem, diazepam and
baclofen).
Experiments were approved by the Federal Institute for Drugs and
Medical Devices (Bundesinstitut fu¨r Arzneimittel und Medizin-
produkte), and by the local Ethics Committees of the Medical Faculty of
Goethe-University Frankfurt (Experiment 1) and the Medical Faculty of
Eberhard-Karls-University Tu¨bingen (Experiment 2).
Experimental design
Experiment 1. The first experiment was designed to investigate the role
of GABAA-ergic neurotransmission on TMS-evoked EEG recordings.
To address this question, we used a pseudo-randomized, placebo-
controlled, double-blinded crossover study to assess the acute effects of a
single oral dose of alprazolam versus zolpidem on TEPs. Alprazolam is a
classical benzodiazepine and allosteric-positive modulator of 1, 2, 3,
and 5 subunit-containing GABAARs, whereas zolpidem is a short-
acting nonbenzodiazepine hypnotic that preferentially binds to 1
subunit-containing GABAARs. Subjects participated in three experi-
mental sessions at least 1 week apart. After baseline measurements,
subjects received a single oral dose of alprazolam (1 mg, Alprazolam-
ratiopharm, ratiopharm), zolpidem (10 mg, Zolpidem-ratiopharm,
ratiopharm), or placebo (P-Tabletten Lichtenstein) (Fig. 1). The order of
drug allocation was pseudo-randomized and balanced across subjects.
Dosages of alprazolam and zolpidemwere chosen because they are effec-
tive standard daily doses in the treatment of patients with anxiety or sleep
disorders, respectively, and according to previously shown sedative ef-
fects by these drugs as indexed by a significant slowing of the saccadic
peak velocity (SPV) (Blom et al., 1990; de Haas et al., 2010).
Postdrug measurements were performed 90 min after drug intake
according to drug pharmacokinetics with plasma levels peaking at1.5 h
after oral intake (Greenblatt and Wright, 1993; Salva` and Costa, 1995)
and in line with previous reports, where TMSmeasures of motor cortical
excitability were significantly altered at this time point (Greenblatt and
Wright, 1993; Salva` andCosta, 1995;Di Lazzaro et al., 2006;Di Lazzaro et
al., 2007).
Experiment 2. The second experiment aimed at assessing the role of
GABAB-ergic neurotransmission for TEPs. To this end, subjects took a
single oral dose of baclofen (50mg Lioresal, Novartis Pharma), diazepam
(20 mg Diazepam-ratiopharm, ratiopharm), or placebo (P-Tabletten
Lichtenstein). Baclofen is a specific GABABR agonist, whereas diazepam
is a classical benzodiazepine binding at 1, 2, 3, and 5 subunit-
containing GABAARs. Diazepam was included into Experiment 2 to
study the specificity of baclofen-mediated modulation of TEPs (see be-
low). Given its similar pharmacological profile with respect to alprazo-
lam (Experiment 1), it also allowed validation of GABAAR-mediated
modulation of TEPs.
As for Experiment 1, subjects participated in three pseudo-
randomized experimental sessions, at least 1week apart, where the effects
of the drugs on TEPs were evaluated 90min after baselinemeasurements
(Fig. 1). Drug doses and time point of postdrug measurements were
chosen according to previous experiments that reported a significant
modulation of TMS parameters for cortical inhibition 1.5 h after drug
intake (Mu¨ller-Dahlhaus et al., 2008) and in line with the pharmacoki-
netics of the two studymedications (Shader et al., 1984;McDonnell et al.,
2006).
SPV measurements
Visually guided SPV is a biomarker of sedation mediated through 1
subunit-containingGABAARs (de Visser et al., 2003; deHaas et al., 2009,
2010). SPV was measured at baseline and after drug intake (Fig. 1).
Subjects sat in front of a screen (eyes to screen distance, 67.5 cm) and
were instructed to make visually guided saccades in response to a white
dot (subtending an angle of view of 1°) on a black screen while the head
wasmaintained in straight position. The dot jumped at random intertrial
intervals of 2–3 s (to prevent anticipation of the next event) horizontally
from one lateral edge to the opposite edge of the screen, subtending an
angle of view of 40°. Both before and after drug intake, 50 trials were
presented. Saccade recordings were obtained by electronystagmography
(ENG) using surface electrodes placed at the outer canthus of each eye.
The ENG raw signals were amplified and bandpass filtered (0.5–70 Hz;
Digitimer D360), digitized at an A/D rate of 10 kHz per channel (CED
Micro 1401; Cambridge Electronic Design), and stored in a laboratory
computer for online visual display and later offline analysis using cus-
tomized data collection and conditional averaging software. ENG data
were then exported into MATLAB (version 2008b; MathWorks), and
in-house-written software was used for manual identification of saccade
onset and offset (Vela´zquez-Pe´rez et al., 2004). SPV (in °/s) was obtained
Figure 1. Timeline of experiments. Peak velocity of visually guided saccades (Saccades) and
EEG responses evoked by single-pulse TMSover the dominant (left) primarymotor cortex (TMS-
EEG) were measured before and 90 min after intake of a single oral dose of alprazolam (1 mg),
zolpidem (10 mg), or placebo (Experiment 1), or diazepam (20 mg), baclofen (50 mg), or
placebo (Experiment 2).
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through third-order polynomial fits of the ENG raw signal. Conditional
SPV averages were calculated for leftward and rightward saccades, and a
grand mean was calculated for each individual, session, and measure-
ment (predrug/postdrug intake).
TMS
Focal TMS of the hand area of left primary motor cortex (M1) was
performed with a figure-of-eight coil (external diameter of each wing, 90
mm) connected to a Magstim 2002 magnetic stimulator (Magstim) with
a monophasic current waveform. The optimal coil position over the
hand area of left M1 for eliciting MEPs in the right abductor pollicis
brevis muscle (APB) was determined as the site where TMS at a slightly
suprathreshold intensity consistently produced the largest MEPs. MEP
recordings were obtained by surface EMG, using Ag-AgCl cup electrodes
in a belly–tendon montage. The EMG raw signal was amplified and
bandpass filtered (20 Hz to 2 kHz; D360 amplifier, Digitimer) and digi-
tized at an A/D rate of 10 kHz per channel (CEDMicro 1401; Cambridge
Electronic Design). The coil was held tangential to the scalp with the
handle pointing backwards and 45 degrees away from the midline. This
orientation induces a lateral–posterior to medial–anterior current in
the brain, activating the corticospinal system preferentially trans-
synaptically via horizontal corticocortical connections (Di Lazzaro et al.,
2008). Restingmotor threshold (RMT)was determined using the relative
frequencymethod (Groppa et al., 2012) andwas defined as theminimum
intensity that was sufficient to elicit an MEP of 50 V peak-to-peak
amplitude in at least five often subsequent trials. The position of the APB
hotspotwasmarkedwith a felt pen on the EEGcap to ensure constant coil
placement throughout the experiment.
High-density EEG recordings during TMS
TMS-evoked EEG potentials were recorded using a TMS-compatible
EEG system (BrainAmp DC, BrainProducts), which prevents EEG am-
plifier saturation and allows continuous data recording during TMS. The
EEG signal was digitized at a sampling frequency of 5 kHz and continu-
ously recorded by 62 electrodes mounted on an elastic cap according to
the standard layout (BrainCap-Fast’n Easy 64Ch, Brain Products). Hor-
izontal eyemovements were recorded by placing an electrode outside the
outer canthus of the eye while an electrode placed below the right eye
recorded vertical eye movements and blinks. The impedance of all elec-
trodes was kept5 k throughout the experiment.
During TMS-EEG recordings, subjects were seated on a comfortable
reclining chair and asked to stay awake with eyes open. A masking noise
was applied by earphones to avoid contamination of the EEG signal by
auditory potentials evoked by the click associated with current discharge
through the TMS coil (Massimini et al., 2005). At baseline and at 90 min
after drug intake, 150 TMS pulses (Experiment 1) or 125 TMS pulses
(Experiment 2) each were applied over the left M1 APB hotspot at an
intensity of 100% RMT. Thus, no or only liminal MEPs were elicited
during TMS-EEG recordings. Therefore, the TEPs were not contami-
nated by somatosensory afferent signals from muscle twitches. The in-
terstimulus interval between TMS pulses was, on average, 5 s (random
intertrial interval variation of 25% to reduce anticipation of the next
trial).
Data processing and TEP analysis
EEG data preprocessing and TEP analysis were
performed using the Fieldtrip open source
MATLAB toolbox (www.ru.nl/fcdonders/
fieldtrip/) (Oostenveld et al., 2011). The EEG
signal was first rereferenced to the linked mas-
toids (channels TP9 and TP10) and down-
sampled to 1 kHz. EEG trials were segmented
from continuously recorded EEG time series
from 500 ms before to 500 ms after TMS
pulses. The TMS artifact was removed by ap-
plying a linear interpolation for 10 ms before
and after the TMS pulse (Thut et al., 2011).
Thereafter, each trial was linearly detrended
and bandpass filtered between 2 and 80 Hz. A
50 Hz notch filter was applied to reduce line
noise contamination. EEG trials were visually
scrutinized, and trials containing artifacts resulting from, for example,
eye movements or muscle activation, were eliminated. The data from 2
subjects in Experiment 1 and 4 subjects in Experiment 2 had to be ex-
cluded from final analysis because of excessive artifact contamination of
the EEG traces.
Artifact-free EEG trials for Experiment 1 (averaged number of trials
across subjects in before and after alprazolam: 126  5 and 119  4;
zolpidem: 125  3 and 109  3; placebo: 123  4 and 128  3) and
Experiment 2 (averaged number of trials across subjects in before and
after diazepam: 107  3 and 99  3; baclofen: 109  3 and 108  3;
placebo: 104 3 and 107 4) were baseline corrected by subtracting the
mean amplitude during an interval between 500 ms and 100 ms
before the TMS onset. TEPs were then calculated by averaging the EEG
signal over all retained trials for each channel. To smooth the TEP, we
used data filtered between 1 and 45 Hz. We considered five TEP compo-
nents (P, positive deflection; N, negative deflection), which were the
most reproducible: P25 (time window of interest [TOI]: 20–30ms), N45
(35–60 ms), P70 (60–80 ms), N100 (85–140 ms), and P180 (150–230
ms) [Experiment 1]; P25 (20–37ms), N45 (40–60ms), P70 (65–85ms),
N100 (88–150 ms), and P180 (150–230 ms) [Experiment 2], in accor-
dance with the literature (Lioumis et al., 2009) (see Fig. 3). TOIs were
chosen on the basis of grand averaged TEPs, which were slightly different
between Experiments 1 and 2 because of intersubject variability of peak
latencies of TEP components (Lioumis et al., 2009) and were kept iden-
tical for the analysis of each predrug and postdrug condition. The ampli-
tude of each TEP component (measured as peak to baseline) was
evaluated before and after drug administration in the specified TOIs.
It has been recently proposed that spontaneous and drug-induced
changes of  oscillations can affect somatosensory-evoked potentials
(Nikulin et al., 2007; Supp et al., 2011). To rule out an effect of drug-
induced changes of neural oscillations on TEPs, aMorlet-wavelet convo-
lution of a width of 5 cycles per wavelet was used to analyze the power
spectra of the EEG signal at baseline (i.e., 500 ms to 100 ms before
TMS) in the  (4–8 Hz),  (8–12 Hz),  (13–30 Hz), and  (30–50 Hz)
frequency bands in Experiment 1 and 2 separately.We then extracted the
average power values for each spectral band aswell as the TEP amplitudes
for each subject before and after drug administration in the channels that
showed a drug-induced change in TEP amplitude (see Results). Spear-
man correlation analyses were run between the TEP amplitude change
(amplitude postdrug  amplitude predrug) and the baseline power
modulation (power postdrug  power predrug) in the different drug
conditions.
Statistics
To evaluate drug effects on SPV, a repeated-measures ANOVA was per-
formed independently for Experiments 1 and 2, with drug (3 levels:
alprazolam, zolpidem, placebo [Experiment 1]; baclofen, diazepam, pla-
cebo [Experiment 2]) and time (2 levels: predrug, postdrug) as within-
subject factors.
To assess whether RMTmeasurements were similar and reproducible
in the three predrug conditions, one-way repeated-measures ANOVAs
Figure 2. Visually guided saccade peak velocity (SPV). SPVwasmeasured before (Pre, black bars) and 90min after (Post, white
bars) intake of a single oral dose of 1 mg alprazolam, 10 mg zolpidem, or placebo (Experiment 1, A), or 20 mg diazepam, 50 mg
baclofen, or placebo (Experiment 2, B). A, Data are means from 20 subjects. B, Data are means from 15 subjects. Error bars
indicate SEM. *Significant differences predrug versus postdrug ( p 0.05).
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with factor drug condition (3 levels: Experiment 1: alprazolam, zolpi-
dem, placebo; Experiment 2: diazepam, baclofen, placebo) were used.
To analyze drug-induced TEP amplitude modulations, multiple de-
pendent sample t tests (predrug vs postdrug intake) were applied on the
level of individual electrodes within each drug condition and each TOI
separately. To correct for multiple comparisons (i.e., electrodes, time
points within TOIs), we conducted a cluster based permutation anal-
ysis (Maris and Oostenveld, 2007) as implemented in FieldTrip
(http://fieldtrip.fcdonders.nl/). That is, a paired t test comparing the
predrug versus postdrug condition was conducted for each electrode at
each time bin within the five different TOIs. t values exceeding an a priori
threshold of p  0.01 were clustered based on adjacent time bins and
neighboring electrodes. Cluster-level statistics were calculated by taking
the sum of the t values within every cluster. The statistical comparisons
were done with respect to the maximum values of summed t values. By
means of a permutation test (i.e., randomizing data across predrug and
postdrug conditions and rerunning the statistical test 1500 times), we
obtained a reference distribution of the maximum of summed cluster t
values to evaluate the statistic of the actual data. Clusters in the original
dataset were considered to be significant at an level of 5% if5%of the
permutations used to construct the reference distribution yielded amax-
imum cluster-level statistic larger than the cluster-level value observed in
the original data.
The reported p values are further Bonferroni-corrected for TOIs (n
5) and predrug and postdrug conditions (n 2), which is reflected by a
corrected  value 0.05/10.
All data are presented as means SEM. if not indicated otherwise.
Results
Experimental procedures and study drugs were generally well
tolerated, except for zolpidem, which caused nausea in one sub-
ject. Other common adverse events were mild to moderate seda-
tion and dizziness, which did not affect the capability of the
subjects to fully comply with the requirements of this study.
Experiment 1
Drug effects on SPV
Repeated-measures ANOVA of drug effects on SPV showed a
significant main effect of TIME (F(1,19) 65.52, p 0.001) and
DRUG (F(2,38)  17.22, p  0.001). In addition, there was a
significant interaction between TIME and DRUG (F(2,38) 
16.18, p 0.001), which was explained by a significant reduction
of SPV 90 min after intake of alprazolam (p 0.001) and zolpi-
dem (p  0.001), whereas placebo had no significant effect on
SPV (p  0.05) (Fig. 2A). Post hoc analysis further showed that
reduction of SPV was greater with alprazolam than with zolpi-
dem (p  0.018). These results are in line with prior reports
demonstrating that visually guided SPV is a biomarker of seda-
tion mediated through 1-subunit-containing GABAARs (de
Visser et al., 2003; de Haas et al., 2009, 2010). This notion is
further supported by the degree of modulation of SPV (after 
predrug) by alprazolam and zolpidem, which showed a signifi-
cant positive correlation (Spearman r2  0.20, p  0.048; data
not shown).
Drug effects on TEPs
RMT was not significantly different between the predrug condi-
tions (alprazolam: 47.8  1.8% maximum stimulator output
[MSO]; zolpidem: 47.4  1.6% MSO; placebo: 48.7  1.9%
MSO; F(2,38) 1.47, p 0.24).
The grand-average TMS-evoked EEG response after single-
pulse TMS of M1 at baseline (Fig. 3A) showed the typical TEP
components (P25, N45, P70, N100, and P180) previously de-
scribed (Lioumis et al., 2009). Topographical surface voltage
maps (Fig. 3A) suggested that early TEPs are located in central
(P25) and contralateral frontal regions (N45). The following
component (P70) was mainly expressed in the stimulated hemi-
sphere, whereas the later TEPs showed a bilateral distribution
over central (N100) and centrofrontal sites (P180) (Bonato et al.,
2006; Ferreri et al., 2011; Veniero et al., 2013).
To determine drug effects on specific TEP components, we
performed a cluster-based permutation analysis of TEP ampli-
tudes in five nonoverlapping TOIs (P25, 20–30 ms; N45, 35–60
ms; P70, 60–80ms; N100, 85–140ms; P180, 150–230ms) before
and after drug intake. Of note, between the predrug conditions,
there were no significant differences (all TOIs p  0.005, cor-
rected formultiple comparisons), whichmay have contributed to
drug-inducedmodulation of TEPs. The benzodiazepine alprazo-
lam increased the N45 potential (pre: 1.93  0.48 V; post:
Figure 3. TEPs before drug intake. Grand-average TEPs (over all electrodes and artifact-free trials) induced by left M1 TMS before intake of alprazolam (red), zolpidem (black), or placebo (blue)
(Experiment 1, A), and diazepam (red), baclofen (black), or placebo (blue) (Experiment 2, B). The time of TMS equals 0 ms. The shaded gray bar represents the part of the EEG trace (10ms) that
was linearly interpolated to remove the TMS-induced artifact. TEP components are labeled according to their polarity and approximate latency. Bottom line indicates topographical distributions of
surface voltages for the most pronounced TEP components (P25, N45, P70, N100, P180; grand-average across predrug measurements in the three drug conditions) for Experiment 1 (A) and
Experiment 2 (B). Maps are scaled and color-coded individually according to their respective maximum (red) and minimum (blue).
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3.07  0.68 V; p  0.001) and reduced the N100 (pre:
3.91 0.54V; post:2.27 0.36V; p 0.001) (Fig. 4A). In
contrast, zolpidem increased the N45 only (pre: 2.68  0.39
V; post:3.87 0.44 V; p 0.001) (Fig. 4A). There were no
significant differences before versus after placebo in any of the
five TOIs (p  0.005, corrected for multiple comparisons)
(Fig. 4A).
Topographical plots of EEG surface voltages of the drug-
induced changes of the N45 (alprazolam, Fig. 5A; zolpidem, Fig.
5C) and N100 (alprazolam, Fig. 5B) showed central and right
hemispheric changes (i.e., changes contralateral to the stimula-
tion site over left M1 hand area). Spearman correlation analysis
revealed a significant positive correlation between the N45 am-
plitude modulation (postdrug predrug intake) in the alprazo-
lam and zolpidem condition (r2 0.29, p 0.014; Fig. 6; average
of common significant channels F2, FC2, FC4, FC6, FT8, C4, C6,
T8, CP4, CP6; compare Fig. 5A,C), suggesting activation of 1-
containing GABAARs as the common mechanism of action.
These results were confirmed by a cluster-corrected analysis
between the postdrug conditions. Compared with placebo, the
N45 potential under alprazolam and zol-
pidem was larger (alprazolam vs placebo:
p  0.004, significant channels: FT8, Cz,
C2, C6, T8, CP2, CP4, CP6; zolpidem vs
placebo: p  0.001, significant channels:
FC2, FC4, FC6, FT8, C2, C4, C6, CPz,
CP2, CP4, CP6, Pz, P2, P6, POz, PO3,
PO4, O2). In addition, the N100 potential
under alprazolam was smaller compared
with placebo (p 0.001, significant chan-
nels: F8, FC2, FC4, FC6, FT8, C2, C4, C6,
T8, CP4, CP6). Finally, theN100 potential
under zolpidem showed a nonsignificant
trend toward a decrease compared with
placebo (p 0.005, corrected formultiple
comparisons; see Material and Methods).
In addition, we studied drug-induced
changes inN45 andN100 potentials at the
level of individual subjects. Although
most of the subjects showed increases in
the N45 potential after intake of alprazo-
lam and zolpidem (see Fig. 8A) and a re-
duction in the N100 potential after intake
of alprazolam (see Fig. 8B), a few subjects
had opposite effects compared with the
group on average.
To investigate whether drug-induced
fluctuations in oscillatory neural activ-
ity underlie the observed modulations
in TEPs, we analyzed EEG power spectra
at baseline (i.e., 500 to 100 ms be-
fore TMS) predrug/postdrug intake and
correlated them with drug-induced TEP
changes. Results showed no significant
correlations between N45 or N100 am-
plitude modulation and power spectra
modulation in any of the frequency
bands analyzed (i.e., , , , and ; for
definition see Material andMethods) by
alprazolam, or between N45 amplitude
modulation and , , , or  power
spectra modulation by zolpidem (all
p  0.05), suggesting that TEP changes
are not based on drug-induced changes in oscillatory neural
activity.
Correlation between drug-induced effects on SPV and TEPs
SPV is a measure of sedation known to be mediated by 1-
containing GABAARs (de Visser et al., 2003). Likewise, the above
data suggested that modulation of the N45 TEP component by
alprazolam and zolpidem is mediated by 1-containing
GABAARs. However, we did not find a correlation between
alprazolam- and zolpidem-induced changes (predrug  post-
drug) of SPV and N45 amplitude (both p 0.05).
Experiment 2
Drug effects on SPV
Repeated-measures ANOVA of drug effects on SPV showed a
significant main effect of TIME (F(1,14)  15.15, p  0.002) but
not of DRUG (F(2,28) 1.84, p 0.110), and a significant inter-
action between TIME and DRUG (F(2,28)  10.17, p  0.001),
which was explained by a significant reduction of SPV 90 min
after intake of diazepam (p  0.002) (Fig. 2B). There was no
Figure 4. Drug-induced modulation of TEPs. TEPs were recorded before (Pre, blue) and after (Post, red) intake of a single oral
dose of alprazolam, zolpidem, or placebo (Experiment 1, A), and diazepam, baclofen, or placebo (Experiment 2, B). Whereas
alprazolam increased theN45and reduced theN100amplitude, zolpidem increased theN45only. Diazepam increased theN45and
decreased the N100 similarly to alprazolam, whereas baclofen increased the N100. Black bars underneath represent significant
drug-induced changes in TEPs. The baseline was corrected between500ms and100ms. To illustrate drug-induced changes
of TEP components, representative channels were chosen for each drug condition. Shades represent SEM. For further informa-
tion see also Figure 3.
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effect of baclofen or placebo on SPV (both
p  0.05). These data confirmed and
extended the results from Experiment 1
that reduction of SPV as a biomarker of
sedation is mediated by 1-subunit-
containing GABAARs (de Visser et al.,
2003; de Haas et al., 2009, 2010), whereas
reduction of SPV is not mediated by
GABABRs.
Drug effects on TEPs
RMT was not significantly different be-
tween the predrug conditions (diazepam:
44.6  1.3% MSO; baclofen: 44.1 
1.13%MSO; placebo: 44.8 1.18%MSO;
F(2,28) 1.12, p 0.34).
The grand-average TMS-evoked EEG
response after single-pulse TMS of the left
M1 confirmed the results from Experi-
ment 1, with the most prominent TEP
components being P25, N45, P70, N100,
and P180 (Fig. 3B). Likewise, topograph-
ical surface voltage maps reproduced that
early TEPs are located in the stimulated
sensorimotor cortex (P25) and contralat-
eral regions (N45), whereas late TEPs are
located in frontocentral sites (Fig. 3B).
As in Experiment 1, a cluster-based
permutation analysis in the five nonover-
lapping TOIs (P25, 20–37 ms; N45,
40–60 ms; P70, 65–85 ms; N100, 88–150
ms; P180, 150–230 ms) showed no signif-
icant difference in TEP amplitudes be-
tween the predrug conditions (all TOIs,
p  0.005, corrected for multiple comparisons). Diazepam in-
creased the N45 (pre:2.19 0.52 V; post:3.71 0.54 V;
p  0.001) and reduced the N100 (pre: 3.01  0.41 V; post:
1.07 0.16V; p 0.001) (Fig. 4B). In contrast, the GABABR
agonist baclofen significantly increased the N100 (pre:2.21
0.34V; post:2.97 0.30V; p 0.003) but had no effect on
the N45 component (p 0.005, corrected for multiple compar-
ison) (Fig. 4B). In addition, there were no significant differences
before versus after placebo in any of the five TOIs (p  0.005,
corrected for multiple comparisons) (Fig. 4B).
Topographical plots of surface voltages of diazepam-induced
changes of TEPs showed a right hemispheric modulation of the
N45 and N100 potentials (i.e., contralateral to the stimulation
site) (Fig. 7A,B), very similar as observed in the alprazolam con-
dition of Experiment 1 (compare Fig. 5A,B). In contrast,
baclofen-induced changes in TEPs were predominantly located
over the left (i.e., stimulated hemisphere) (Fig. 7C).
These drug-induced effects onTEPs could be confirmedwhen
comparing the postdrug TEP amplitudes across drug conditions.
Compared with placebo, the N45 potential under diazepam was
larger (p 0.001, significant channels: FC2, FT8, Cz, C2, C4, C6,
T8, CP2, CP4, CP6, TP8, P2, P4, P6, P8, PO4, PO8, O2) and the
N100 potential under diazepam was smaller (p 0.002, signifi-
cant channels: FC2, FC4, FC6, FT8, C2, C4, C6, T8, CP4, CP6,
TP8). The N100 potential under baclofen showed a nonsignifi-
cant trend toward an increase compared with placebo (p 0.04
in channels: C3, C1, CP5, CP3, P5, P3, and PO3).
In addition, investigation of drug-induced changes in N45
andN100 potentials (postdrug/predrug) at the level of individual
subjects showed that most of the subjects showed an increase in
the N45 potential (Fig. 8C) and a decrease in the N100 potential
(Fig. 8D) after intake of diazepam, whereas most of the subjects
showed an increase in the N100 potential after intake of baclofen
(Fig. 8D). As in Experiment 1, few subjects showed opposite drug
effects compared with the group on average.
Importantly, these drug-induced modulations of TEP com-
ponents cannot be explained by drug-induced changes in oscilla-
Figure 5. Topographical plots for TEP components N45 and N100 before and after intake of alprazolam and zolpidem (Experi-
ment 1). Topographical distributions of the TEP amplitudes (color coded inV) before (PRE, left column) and after (POST, middle
column)alprazolam(A, N45;B, N100) andzolpidem(C, N45). Large crosses indicate site of TMSof thehandareaof left-hemispheric
M1. Right column, t-statisticmaps of the TEP amplitude postdrug versus predrugdifferences. Crosses indicate significant channels,
predominantly in the nonstimulated right hemisphere. Red represents increase in negativity; blue represents decrease in nega-
tivity. For further details, see Material and Methods.
Figure 6. Correlation between modulation of the N45 amplitude by alprazolam and zolpi-
dem (Experiment 1). A significant correlation was found between modulation of the N45 am-
plitude by alprazolam (x-axis) and modulation of the N45 amplitude by zolpidem ( y-axis)
(Spearman correlation coefficient, r 2 0.29, p 0.014).
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tory neural activity, as we did not find any significant correlation
between diazepam- or baclofen-induced changes in , , , or 
power spectra at baseline (i.e., 500 to 100 ms before TMS)
predrug/postdrug intake and diazepam- or baclofen-induced
N45 and N100 amplitude changes, respectively (all p  0.05).
These findings thus confirm and extend the results from Experi-
ment 1 that enhancement of neurotransmission through
GABAARs by diazepam increases early (N45) and decreases late
(N100) TEP components predominantly in the nonstimulated
hemisphere, enhancement of neurotransmission through the
GABABR by baclofen selectively increases the N100 in the stim-
ulated hemisphere.
Correlation between drug-induced effects on SPV and TEPs
Similar as for alprazolam in Experiment 1, we did not find a
significant correlation between diazepam-induced changes of
SPV and N45 amplitude (p 0.05).
Discussion
Using pharmacological modulation of neurotransmission
through the GABAAR and GABABR in combination with TMS-
EEG, we show here, for the first time, that activity of 1-subunit-
containing GABAARs contributes to early TEPs (the N45
potential), whereas activity of GABABRs contributes to a later
TEP (the N100 potential). These findings are discussed in detail
below.
The role of GABAARs in TEPs
A contribution of GABAAergic neurotransmission to TEPs has
been investigated before in two studies using paired-pulse TMS at
a short interstimulus interval of 3 ms to
measure short-interval intracortical inhi-
bition, a marker of GABAAR activity (Zi-
emann et al., 1996).MEP amplitudes were
in line with short-interval intracortical in-
hibition in both studies, whereas the ef-
fects of paired-pulse TMS on TEPs were
inconsistent. In one study, paired-pulse
TMS had no significant effect on the N45
and N100 amplitudes compared with
single-pulse TMS (Paus et al., 2001),
whereas the other study demonstrated a
focal increase in N45 and N100 ampli-
tudes in the stimulated hemisphere by
paired-pulse TMS (Ferreri et al., 2011).
In this study, we applied subtype-
specificmodulators at theGABAAR to ex-
plore the contribution of GABAAergic
neurotransmission on specific TEP com-
ponents. In Experiment 1, the positive
modulators at the GABAAR alprazolam
and zolpidem significantly increased the
N45 amplitude. Moreover, analysis of
common channels of significant drug ef-
fects showed that the increase in the N45
potential in both drug conditions was
positively correlated, suggesting a com-
mon underlying mechanism. In Experi-
ment 2, we replicated the effect of
GABAARs on the N45 potential by the
classical benzodiazepine diazepam. As al-
prazolam, zolpidem, and diazepam show
a common receptor profile targeting the
1-subunit of the GABAAR, our data
strongly suggest that activation of 1-subunit-containing
GABAARs contributes to the generation of the N45 potential.
Topographical plots of surface voltages of drug-induced
changes in the N45 potential revealed that these changes were
predominantly located in the hemisphere contralateral to the site
of stimulation. In contrast, previous reports showed a dose-
dependent increase in early TEPs at the site of stimulation during
midazolam-induced loss of consciousness, whereas later TEPs
were suppressed by midazolam along with a breakdown in corti-
cal effective connectivity (Ferrarelli et al., 2010). This discrepancy
may be the result of the different sites of stimulation (right pre-
motor cortex in the previous study, left M1 in our study) or the
level of consciousness (loss of consciousness in the previous
study, slight sedation in our study). However, comparison be-
tween the two studies is also limited by the fact that topographical
distributions of surface voltages do not allow to make conclusive
inferences about the location of changes in the underlying neu-
ronal circuits. To address this issue, source modeling analysis on
TMS-evoked EEG responses is needed. Whatever the underlying
mechanism, the topography of drug-induced TEP changes
matched the topography of the maximum negativity of the N45
before drug intake (compare right vs left columns in Figs. 5A,C
and 7A).
Notably, we did not find a correlation between drug-induced
changes in our behavioral measure (SPV) and modulation of the
N45 potential by alprazolam and zolpidem (Experiment 1) or
diazepam (Experiment 2). Because the drug-induced changes in
both measures are mediated by activation of 1-subunit-
containing GABAARs, this lack of a correlation suggests a differ-
Figure 7. Topographical plots for TEP components N45 and N100 after intake of baclofen and diazepam (Experiment 2).
Topographical distributions of the TEP amplitudes (color coded inV) before (PRE, left column) and after (POST, middle column)
diazepam (A, N45; B, N100) and baclofen (C, N100). Large crosses indicate site of TMS of the hand area of left-hemispheric M1.
Right column, t-statistic maps of the TEP amplitude postdrug versus predrug differences. Crosses indicate significant channels,
predominantly in the nonstimulated right hemisphere for diazepam, and in the stimulated left hemisphere for baclofen. Red
represents increase in negativity; blue represents decrease in negativity. For further details, see Material and Methods.
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ent role for GABAAergic neurotrans-
mission in visuomotor processes in spe-
cific frontoparietal networks (i.e., frontal,
supplementary, and parietal eye fields)
(Luna et al., 1998) and signal propagation
of the N45 from left M1 stimulation in a
widespread distributed cortical network.
In contrast to the similar effect of al-
prazolam, zolpidem, and diazepamon the
N45 amplitude, alprazolam and diaze-
pam, but not zolpidem, reduced the N100
amplitude. Topographical plots of surface
voltages showed that the N100 potential,
after drug intake, is lateralized to the site
of stimulation but distributed across
both hemispheres before drug intake
(compare Figs. 5B and 7B,C). Drug-
induced changes of the N100 potential
showed a spatial dissociation: whereas
the alprazolam- and diazepam-induced
N100 amplitude decreases were only sig-
nificant in channels in the hemisphere
contralateral to the stimulation (compare
Figs. 5B and 7B), baclofen-induced N100
amplitude increases were located in close
proximity to the stimulation site (com-
pare Fig. 7C).
The mechanisms of these drug effects
are not clear. Reduction of the N100 po-
tential in the hemisphere contralateral to
the stimulation by alprazolam and diaze-
pam, but not zolpidem, may be explained
by a sedation-related suppression of signal propagation from
the stimulated to the nonstimulated hemisphere (compare
Figs. 5B and 7B). An extensive breakdown of long-range cor-
ticocortical effective connectivity as measured by late TEPs has
been observed during midazolam-induced loss of conscious-
ness (Ferrarelli et al., 2010) and during NREM sleep (Massi-
mini et al., 2005).
Alternatively, propagation of the N100 from the stimulated to
the nonstimulated hemisphere may involve cortico-subcortical-
cortical loops (e.g., via the thalamus). The thalamus is a major
subcortical hub and essential for sensory processing and motor
output (Huguenard and McCormick, 2007). Importantly,
thalamocortical cells have an excitatory input but are encapsu-
lated by two inhibitory shell-like nuclei: the thalamic reticular
and perigeniculate nuclei (RT/PGN cells). This sophisticated and
well-balanced excitatory/inhibitory drive of thalamocortical cells
is critical for orchestrating thalamocortical oscillations. It is
known from animal experiments that RT and PGN cells provide
intrathalamic desynchronizing activity mediated by 3-GABAARs,
whereas 1-GABAARs located at the level of thalamocortical cells
are pro-oscillatory (Huguenard and McCormick, 2007). Given
the higher binding affinity of alprazolam and diazepam than zol-
pidem to 3-subunit-containing GABAARs, alprazolam/diaze-
pammay favor antioscillatory activity within the thalamocortical
loop, thus suppressing thalamocortical communication. This
disruption of thalamocortical connectivity by alprazolam/diaze-
pam may alternatively explain reductions in N100 signal propa-
gation from the stimulated to the nonstimulated hemisphere
under these conditions. However, further analyses, including
source modeling, are needed to clarify precisely the propagation
of TEPs and its change by drugs.
Finally, cellular experiments demonstrated that activation of
GABAARs inhibits sIPSP generated in neocortical and hip-
pocampal pyramidal neurons by GABABRs (Lopantsev and
Schwartzkroin, 1999; Thomson and Destexhe, 1999), probably
through an increase in intracellular chloride concentration that
inhibits the potassium conductance underlying the GABABR-
mediated sIPSP (Lenz et al., 1997). This may be another mecha-
nism to account for the observed decrease of the N100 amplitude
by alprazolam and diazepam. This explanation would fit with the
observation that diazepam, and lorazepam, another benzodiaz-
epine, resulted in shortening of the cortical silent period duration
(Inghilleri et al., 1996; Kimiskidis et al., 2006), a TMS-EMGmea-
sure of GABABergic neurotransmission (Siebner et al., 1998).
The role of GABABR-mediated neurotransmission for TEPs
The N100 is the most pronounced and reproducible TEP com-
ponent and has been related to sIPSP (Nikulin et al., 2003; Bender
et al., 2005). Specifically, the N100 amplitude is increased under
augmented inhibition, such as during preparation to resist a
forthcoming TMS evoked movement (Bonnard et al., 2009), al-
though it is decreased during preparation to assist a TMS-evoked
movement (Nikulin et al., 2003), motor response preparation
(Bender et al., 2005), ormotor performance (Kicic´ et al., 2008). A
recent study showed that the N100 amplitude is related to the
duration of the cortical silent period (Farzan et al., 2013). In
Experiment 2 of our study, baclofen, but not any of the GABAAR
modulators, increased the N100 amplitude, thus strongly corrobo-
rating a role of GABABRs in the generation of the N100 potential.
Importantly, none of these drug-inducedmodulations of TEP
components can be explained by drug-induced changes in oscil-
latory neural activity (Supp et al., 2011), as we did not find any
Figure 8. Drug-induced changes of TEPs (single subject data). Scatter plots of individual amplitudemodulations (postdrug
predrug) of theN45 (A,C) andN100 (B,D) TEP components fromExperiments 1 and2, respectively. The amplitudeswere extracted
for common significant channels in the alprazolamand zolpidemcondition (N45:A, compare Fig. 5A, C), significant channels in the
alprazolam condition (N100:B, compare Fig. 5B), and significant channels in the diazepam condition (N45: C, compare Fig. 7A).D,
Data were taken from significant channels in the diazepam and baclofen condition, respectively (as diazepam changed the N100
contralateral to the stimulation site,whereas baclofen changed theN100 ipsilateral to the stimulation site; compare Fig. 7B, C). For
placebo, changes in the N100 were extracted from significant channels in diazepam and baclofen conditions. Error bars indicate
group mean SEM.
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significant correlation between drug-induced changes in -,
[alpha-],-, or-power at baseline (i.e.,500 to100ms before
TMS) and drug-induced N45 and N100 amplitude changes.
In clinical practice, it would be highly interesting to use TMS-
EEG recordings to study, or even monitor longitudinally, the
state of neural circuits in individual patients. Previous work in
healthy subjects showed that TMS-evoked cortical responses es-
sentially reflect deterministic properties of the stimulated net-
work and thus, indeed, may be used to detect longitudinal
changes in the state of cortical circuits (Casarotto et al., 2010).
However, our pharmaco-TMS-EEGexperiments showednotable
interindividual variability of drug effects on TEPs, with some
subjects showing opposite drug effects with respect to the group
average. Thus, interpretation of TMS-EEG recordings at the
single-subject level is difficult andmaybe limited. Clearly, further
studies are needed to explore the full potential of TMS-EEG re-
cordings for analysis of perturbation-induced (i.e., drug-,
training-, noninvasive brain stimulation-, or disease-related) ef-
fects on cerebral networks in individual subjects/patients.
In conclusion, here we used a novel pharmaco-TMS-EEG
approach to study the effect of CNS-active drugs directly on
cortical activity. Our data demonstrate a differential effect of
GABAAergic versus GABABergic neurotransmission on spe-
cific components of TMS-evoked EEG activity. Findings sug-
gest that TMS-EEG may be used to study GABAAergic and
GABABergic inhibition in neurological and psychiatric disor-
ders, in which abnormal cortical inhibition has been impli-
cated in the pathophysiology, such as epilepsy or schizophrenia
(Jones-Davis and Macdonald, 2003; Lewis et al., 2005). In addi-
tion, pharmaco-TMS-EEG offers the opportunity to study the
actions of CNS-active drugs on human cortex in greater detail
than it is hitherto possible with TMS or EEG alone.
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